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BACKGROUND: There is a paucity of research describing health-related quality of life (HRQOL) in older adults considered for
advanced heart failure surgical therapies. Using data from our SUSTAIN-IT (Sustaining Quality of Life of the Aged: Heart
Transplant or Mechanical Support) study, we aimed to compare HRQOL among 3 groups of older (60–80 years) patients
with heart failure before heart transplantation (HT) or long-term mechanical circulatory support (MCS) and identify factors
associated with HRQOL: (1) HT candidates with MCS, (2) HT candidates without MCS, or (3) candidates ineligible for HT and
scheduled for long-term MCS.

Downloaded from http://ahajournals.org by on April 26, 2022

METHODS AND RESULTS: Patients from 13 US sites completed assessments, including self-reported measures of HRQOL
(EuroQol-5 Dimension Questionnaire, Kansas City Cardiomyopathy Questionnaire–12), depressive symptoms (Personal Health
Questionnaire–8), anxiety (State-Trait Anxiety Inventory–state form), cognitive status (Montreal Cognitive Assessment), and
performance-based measures (6-minute walk test and 5-m gait speed). Analyses included ANOVA, χ2 tests, Fisher’s exact
tests, and linear regression. The sample included 393 patients; the majority of patients were White men and married. Long-
term MCS candidates (n=154) were significantly older and had more comorbidities and a higher New York Heart Association
class than HT candidates with MCS (n=118) and HT candidates without MCS (n=121). Long-term MCS candidates had worse
HRQOL than HT candidates with and without MCS (EQ-5D visual analog scale scores, 46±23 versus 68±18 versus 54±23
[P<0.001] and Kansas City Cardiomyopathy Questionnaire–12 overall summary scores, 35±21 versus 60±21 versus 49±22
[P<0.001], respectively). In multivariable analyses, lower 6-minute walk distance, higher New York Heart Association class,
depressive symptoms, and not being an HT candidate with MCS were significantly associated with worse overall HRQOL.
CONCLUSIONS: Our findings demonstrate important differences in overall and domain-specific HRQOL of older patients with
heart failure before HT or long-term MCS. Understanding HRQOL differences may guide decisions toward more appropriate
and personalized advanced heart failure therapies.
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A

pproximately 6.2 million US adults have heart failure (HF), with an incidence approaching 21 per
1000 population after 65 years of age.1 Many HF

subgroups have poor survival. Among Medicare beneficiaries with HF, the 1-year mortality rate is 29.6%.2
Patients with advanced HF have even worse survival,
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CLINICAL PERSPECTIVE
What Is New?

• In a cohort of older patients with advanced
heart failure, health-
related quality of life
(HRQOL) was poor to fair; patients who were
ineligible for heart transplantation and scheduled for implantation of long-term mechanical
circulatory support had worse HRQOL than
patients awaiting heart transplantation with or
without mechanical circulatory support.
• Being a heart transplant candidate with mechanical circulatory support was associated
with better HRQOL compared with being a
heart transplant candidate without mechanical circulatory support, whereas a decreased
6-
minute walk test distance, higher New
York Heart Association class, and depressive symptoms were associated with worse
HRQOL in these older patients with heart
failure.

What Are the Clinical Implications?
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• Understanding differences in HRQOL before
alternative advanced surgical therapies (ie,
heart transplantation and long-term mechanical circulatory support) contributes to more
informed shared decision-making discussions
for older patients with heart failure considering
these treatment options.
• Differences in domain-
specific HRQOL (eg,
problems with mobility, usual activities, social
functioning, anxiety/depression, and pain/discomfort and potentially worsening heart failure symptoms) in older patients before heart
transplantation and long-term mechanical circulatory support provide important individualized targets for treatment, especially for those
awaiting long-
term mechanical circulatory
support as they reported more problems than
heart transplant candidates.

Nonstandard Abbreviations and Acronyms
6MWT
BTC
BTT
DT
EQ-5D-3L
HT
KCCQ-12

6-
minute walk test
bridge to candidacy
bridge to transplantation
destination therapy
EuroQol-5 Dimension
Questionnaire
heart transplantation
Kansas City Cardiomyopathy
Questionnaire–12

MOMENTUM 3 Multicenter Study of MagLev
Technology in Patients
Undergoing Mechanical
Circulatory Support Therapy
With HeartMate 3
OSS
overall summary score
SUSTAIN-IT
Sustaining Quality of Life of the
Aged: Heart Transplant or
Mechanical Support

with 1-year mortality rates of 75% to 89%.3 Treatment
goals for these patients are focused not only on improving survival but also on improving health-related
quality of life (HRQOL).
Studies demonstrate a range of HRQOL outcomes
in adult patients with advanced HF, varying by disease
severity,4–12 but have rarely exclusively focused on
older patients (ie, ≥60 years), despite the prevalence
of HF being greatest in the elderly. In patients with ambulatory advanced HF, REVIVAL (Registry Evaluation
of Vital Information for VADs in Ambulatory Life) investigators reported on outcomes in patients with a
median of 60 years of age (interquartile range [IQR],
54–68 years of age),5 whereas MedaMACS (Medical
Arm of Mechanically Assisted Circulatory Support) investigators examined outcomes in patients who were
on average 59 years of age (mean±SD, 59±11 years of
age).4 Studies of cohorts of patients who were more
severely ill with advanced HF als o included adult patients of all ages. Patients enrolled in the MOMENTUM
3 (Multicenter Study of MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy
with HeartMate 3) trial were a median of 64 years of
age (range, 19–81 years of age; HeartMate 3) and a
median of 61 years of age (range, 24–78 years of age;
HeartMate II).9 A European cross-sectional study of patients undergoing heart transplantation (HT) by Emin et
al8 included patients whose median age in years for HT
candidates with MCS was 49.6 (IQR, 39.1–55.3 years
of age) and for HT candidates on medical therapy was
47.1 (IQR, 40.6–56.7 years of age). Thus, we lack an
understanding of HRQOL outcomes in older patients
with advanced HF, including those who may be eligible
for advanced surgical therapies.
As HT and mechanical circulatory support (MCS)
implantation, advanced surgical treatment options for
patients with HF, are being offered more frequently to
the elderly,13,14 gaps in the literature also exist regarding HRQOL benefits, based on intended goal of therapy,
which may inform how much these patients may benefit
and which therapies may provide more HRQOL-related
benefit. White-
Williams and colleagues15 compared
baseline HRQOL in adult patients with advanced HF
before left ventricular assist device (LVAD) implantation
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enrolled in the INTERMACS (Interagency Registry for
Mechanically Assisted Circulatory Support) database
by implant strategy (bridge to transplantation [BTT],
bridge to candidacy [BTC], and destination therapy
[DT]), which did not include patients awaiting HT without MCS. Similarly, in the MOMENTUM 3 trial, investigators identified baseline differences in HRQOL in adult
patients with BTT and BTC versus DT implant strategies
that also did not include a group of patients who were
being medically treated and awaiting HT.12 Groups in
the study of HRQOL by Emin et al8 included adult patients evaluated for HT, listed for HT on medical therapy, listed for HT on LVAD therapy, and after HT, but did
not include a DT MCS group. Although these studies
compared HRQOL in patients with either MCS and/or
HT as an intended goal of therapy, none included all of
the following 3 groups: HT (with or without MCS as a
pre-HT management strategy) and DT MCS. We examined baseline differences in HRQOL by age in 3 separate
articles focused on patients undergoing HT, DT MCS, or
MCS (combining patients with BTT and DT MCS), yet we
did not include comparative analyses by intended goal
of therapy.7,16,17 Thus, a “head-to-head” comparison of
baseline HRQOL in a contemporary cohort of older patients with advanced HF who are candidates for HT (with
or without MCS while awaiting HT) or DT MCS remains
to be elucidated. To address this gap in knowledge, as
optimizing HRQOL is often a primary goal of therapy for
older patients, we present findings from the SUSTAIN-IT
(Sustaining Quality of Life of the Aged: Heart Transplant
or Mechanical Support) study, whose primary aim is
to compare HRQOL outcomes in older patients (60–
80 years of age) with advanced HF who undergo HT or
DT MCS from before to 2 years after these surgeries.
In this report from the SUSTAIN-IT study, we compared HRQOL in older patients with advanced HF at
baseline (ie, before undergoing HT or DT [long-
term]
MCS). HT candidates were divided into 2 groups (ie,
those awaiting HT with MCS and those awaiting HT without MCS) to provide insight into differences in HRQOL
between these 2 alternative pre-HT management strategies. Thus, we aimed to compare HRQOL among the following 3 groups of patients: (1) HT candidates with MCS,
(2) HT candidates without MCS, and (3) those deemed
ineligible for HT and therefore candidates for long-term
MCS. We also aimed to identify patient factors associated with HRQOL. We hypothesized that (1) baseline
overall and domain-specific HRQOL of long-term MCS
candidates would be different from baseline HRQOL of
the HT candidate groups, and (2) factors associated with
overall HRQOL would include patient group, indicators
of HF severity (eg, New York Heart Association [NYHA]
class and functional capacity), and psychological variables (ie, anxiety and depressive symptoms).
Our nomenclature regarding the 3 groups of patients in this article is based on the recent Centers for
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Medicare and Medicaid National Coverage Decision to
remove intent-to-treat criteria of BTT and DT by removing the requirement that patients with BTT MCS must
be active on the United Network for Organ Sharing
(UNOS) waiting list for HT. Thus, instead of BTT, we
use the phrase “HT candidate with MCS,” and instead
of DT, we use the phrase “long-term MCS.” We defined
HRQOL as “the functional effect of an illness and its
consequent therapy upon a patient, as perceived by
the patient”18 and used the theoretical framework by
Spilker and Revicki18 (modified to include caregivers) to
guide our research as it is focused on the influence of
disease and treatment on HRQOL outcomes.

METHODS
The data that support the findings of this study are
available from the corresponding author upon reasonable request.

Design, Settings, and Sample
We used an observational, cross-sectional, multisite
design to compare HRQOL in patients with HF before
HT or long-term MCS. Patients were recruited from 13
US medical centers with HT and MCS programs that
participated in the SUSTAIN-IT study. Study inclusion
criteria were presence of advanced HF; 60 to 80 years
of age; able to speak, read, and understand English;
and listed with the UNOS for HT or being considered or scheduled for long-term primary MCS, specifically LVAD implantation. Second-
generation and
third-generation US Food and Drug Administration–
approved and investigational LVADs were permissible.
HT candidates with MCS could have had 1 or more
LVADs. Long-
term MCS candidates were recruited
only if they had a low probability of becoming HT candidates (<35% chance at 2 years), per opinions of site
investigators. We identified this enrollment cutoff to ensure, as best as possible, that patients in the long-term
MCS group would remain in this group for the duration of the study and not cross over to HT candidacy,
at which time they would be censored. HT candidates
listed for retransplant, multiple organ transplant, and/
or those with right or bi-ventricular assist devices
were excluded from the study. Long-term MCS candidates with prior ventricular assist devices were also
excluded. The study was approved by all site institutional review boards, and participants provided written
informed consent.

Instruments, Data Collection, and
Procedures
Patients completed the following self-reported assessments of HRQOL: EuroQol-5 Dimension Questionnaire
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(EQ-5D-3L19; a 6-
item generic measure of HRQOL)
and Kansas City Cardiomyopathy Questionnaire–
12
(KCCQ-1220; a 12-
item, HF-
specific measure of
HRQOL; Table S1). The EQ-5D-3L includes 5 dimensions of health (mobility, self-
care, usual activities,
pain/discomfort, and anxiety/depression) and a visual
analog scale (VAS; 0 [worst]–
100 [best] imaginable
health state). The KCCQ-12 has 4 domains (physical
limitations, symptom frequency, social limitations, and
quality of life) and an overall summary score (OSS) created from the domain scores. Clinically important differences for the EQ-5D-3L17,21 and the KCCQ-1220 are
10 and 5 points, respectively. Patients also completed
an 8-item screen for depressive symptoms (Personal
Health Questionnaire– 8),22 a 20-item measure of current anxiety (State-Trait Anxiety Inventory–state form),23
an interviewer-administered screen of cognitive function (Montreal Cognitive Assessment),24 and the following 2 researcher-
monitored, performance-
based
measures as surrogate markers of functional capacity
and frailty, respectively (Table S1): 6-minute walk test
(6MWT)25 and 5-m gait speed.26
Assessments were administered as follows: (1) in the
HT candidate with MCS group after listing with UNOS
while on MCS, (2) in the HT candidate without MCS
group after listing with UNOS while on medical therapy,
and (3) in the long-term MCS group after being considered and/or scheduled for long-term MCS.
Sociodemographic characteristics (eg, age, sex,
race, marital status, work status, and insurance) and
clinical variables (eg, etiology of HF, medical/surgical
history, NYHA class, INTERMACS profile, and UNOS
status) were collected by sites from patient medical
records and/or directly from the Society of Thoracic
Surgeons INTERMACS database via secure monthly
data downloads.

Statistical Analysis
Demographic characteristics, clinical variables, and
assessments were summarized using mean±SD, median (first quartile, third quartile), or count (percentage)
as appropriate. Group comparisons (ie, analysis of
variance [ANOVA], χ2 tests, or Fisher’s exact test) were
used to test the hypothesis that baseline HRQOL of
long-term MCS candidates is different from baseline
HRQOL of HT candidate groups.
Item-level missing data on the HRQOL assessments
were imputed via the within-group respondent mean (if
continuous) and mode (if categorical) to avoid group
cross-contamination.27 This imputation method was
used if <15% of item-level data were missing, except
for the KCCQ-12, wherein imputation was not used per
scoring instructions. For 58 patients with 6MWT data
missing for reasons other than inability to walk or patient being too sick or too tired to walk (for whom we
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imputed a value of 0), we used model-predicted single
imputation based on a least squares regression model
with NYHA class at enrollment and KCCQ-12 symptom frequency as explanatory variables. We also conducted sensitivity analyses by fitting separate models
for each outcome using solely observed 6MWT values
(no imputation).
The second hypothesis (factors associated with
overall HRQOL would include patient group, indicators of HF severity, and psychological variables) was
tested using univariable and multivariable linear least
squares regression models. We modeled separately
overall HRQOL scores (EQ-
5D-
3L VAS and KCCQ-
12 OSS). In the univariable models, the initial pool of
baseline variables included age, sex, race, marital status, working status, highest level of education more
than high school, insurance type, Personal Health
Questionnaire– 8, State-Trait Anxiety Inventory–state
form, patient group (ie, HT candidate with MCS, HT
candidate without MCS, and long-term MCS), method
of payment for medical care, history of smoking, comorbidities (myocardial infarction, diabetes, hypertension, kidney disease, arrhythmia, hyperlipidemia),
Montreal Cognitive Assessment, and 6MWT. We used
an entry point of α=0.3 in the univariable models to define the candidate pool for multivariable model building.
Multivariable models were created by including each
variable significant univariately at the 0.3 α level, excluding variables that were collinear with the outcome
or poorly reported.
Between-
center differences for patient demographic and clinical characteristics and outcomes were
assessed. Statistical significance was established at a
2-sided α=0.05, and no adjustments were made for
multiplicity. Statistical analyses were performed using
SAS version 9.4 (SAS Institute, Cary, NC) and R version
3.6.1 (R Foundation for Statistical Computing, Vienna,
Austria). Dr Andrei had full access to all data in the
study and takes responsibility for its integrity and the
data analysis.

RESULTS
Between October 1, 2015 and December 31, 2018,
from a pool of 1141 patients with advanced HF (649 HT
candidates and 492 long-term MCS candidates), 635
patients were approached (n=369 HT candidates and
n=266 long-term MCS candidates), and 396 (n=241
HT candidates and n=155 long-term MCS candidates)
were recruited to participate in the SUSTAIN-IT study
(Figure). A total of 2 HT candidates and 1 long-term
MCS candidate who were enrolled were deemed ineligible and immediately withdrawn, leaving a final sample
size of 393 patients (239 HT candidates and 154 long-
term MCS candidates). Among those patients listed for
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Figure 1. Timeline and consort flow diagram for patients before long-term MCS or HT.
BTT indicates bridge to transplantation; DT, destination therapy; HT, heart transplantation; and MCS, mechanical circulatory support.
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HT, there were 118 with MCS and 121 without MCS.
Reasons for not approaching candidates included timing of surgery and administrative issues (eg, staffing
issues), being too sick, and other reasons. Reasons
for refusal to participate for those approached included
lack of interest, too sick, and other (Figure).
The majority of patients were White men and married, and 67% had more than a high school education
(Table 1). Long-term MCS candidates were older, on
average, than HT candidates with and without MCS,
although substantial overlap was observed between
groups (Figure S1). Long-term MCS candidates also
had significantly more comorbidities and a higher
NYHA class at enrollment (Table 1).

Rates of Assessment Completion and
Psychometrics
Baseline completion of assessments varied based on
type of assessment and group. Rates of patient completion of self-report assessments and the interview were
excellent (ranges, 92%–99% and 91%–92%, respectively), whereas completion rates for the performance-
based measures (6MWT and 5-m gait speed) were
lower (range, 24%–66%) and lowest for patients awaiting long-term MCS (Table S2). The most frequently
reported reason for incomplete performance-
based
measures was that the participant was too sick, which
varied by site (1%–22%; Table S3). Sensitivity analyses based on observed (unimputed) 6MWT data show
that, for each outcome, model coefficients are not impacted substantially; their directionality and statistical

significance remaining unchanged. Cronbach’s α were
acceptable for the outcome variables (EQ-5D-3L, 0.72;
KCCQ-12 OSS, 0.90) in our SUSTAIN-IT study cohort.

Baseline Comparisons of HRQOL Among
Groups
Baseline overall HRQOL for the entire sample was poor
to fair (EQ-5D-3L mean±SD VAS score, 55±23; KCCQ-
12 mean±SD OSS, 47±23; Table 2). Significant differences were found among groups. Long-
term MCS
candidates had worse HRQOL than HT candidates
with and without MCS (EQ-
5D-
3L mean±SD VAS
score, 46±23 versus 68±18 versus 54±23 [P<0.001];
KCCQ-12 mean±SD OSS, 35±21 versus 60±21 versus 49±22 [P<0.001], respectively), whereas HT candidates with MCS had the highest scores. Regarding
EQ-5D-3L dimensions, >50% of the total sample reported problems with mobility, usual activities, and
pain/discomfort. Long-term MCS candidates had significantly more problems with mobility, self-care, usual
activities, and anxiety/depression than HT candidates
with and without MCS (Table 2). No group differences
were detected for pain/discomfort. Although reports of
“extreme problems” were generally low for the aforementioned dimensions, long-
term MCS candidates
reported more extreme problems regarding mobility,
self-care, and usual activities than both groups of HT
candidates (Table S4). KCCQ-12 domain scores also
differed significantly among groups. Long-term MCS
candidates reported more physical and social limitations, higher symptom frequency, and worse quality
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363 (133, 109, 121)

382 (143, 118, 121)

49 (15, 13, 21)

Education, more than high
school

Currently working

Working part-time vs
full-time

67 (18)

245 (67)

302 (78)

57 (15)
128 (34)
179 (47)

II

III

IV

33 (13)
189 (73)
37 (14)

Profile 1

Profiles 2 to 3

Profiles 4 to 7

INTERMACS profile at
enrollment

18 (5)

I

259 (146, 113, NA)

24 (6)

Other

NYHA class at study
enrollment

187 (48)

Dilated cardiomyopathy

382 (149, 113, 120)

41 (27)

16 (11)

118 (81)

12 (8)

131 (88)

17 (11)

1 (1)

0 (0)

8 (5)

65 (42)

81 (53)

28.4±6.5

150 (38)
28.4±5.5

182 (46)

393 (154, 118, 121)

346 (148, 78, 120)

113 (73)

8 (53)

7 (47)

21 (15)

93 (70)

118 (78)

3 (2)

126 (82)

122 (79)

68.6±5.2

243 (62)

Ischemic cardiomyopathy

Heart failure etiology

Clinical characteristics

BMI at time of study
enrollment, kg/m2

Private insurance

Medicare/Medicaid

Insurance type

393 (154, 118, 121)

388 (151, 116, 121)

Marital status: married/
domestic partners

6 (2)

30 (61)

386 (150, 118, 118)

Ethnicity: Hispanic or Latino

323 (83)

315 (80)

19 (39)

390 (154, 118, 118)

White race

Full-time

393 (154, 118, 121)

Male sex

66.0±4.6

Total sample, n=393†

Part-time

393 (154, 118, 121)

Available sample total,
by group*

Age, y

Demographic characteristics

Variable

Long-term MCS
candidates, n=154†
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Table 1. Patient Demographic and Clinical Characteristics at Baseline

21 (19)

71 (63)

21 (19)

15 (13)

39 (35)

43 (38)

16 (14)

6 (5)

57 (48)

55 (47)

29.9±4.7

49 (42)

69 (58)

7 (54)

6 (46)

23 (19)

69 (63)

89 (77)

2 (2)

94 (80)

99 (84)

64.4±3.3

HT candidates with MCS,
n=118†

NA

NA

NA

33 (28)

72 (60)

13 (11)

2 (2)

10 (8)

65 (54)

46 (38)

27.5±4.3

60 (50)

61 (50)

15 (71)

6 (29)

23 (19)

83 (69)

95 (79)

1 (1)

103 (87)

94 (78)

64.0±2.9

HT candidates without
MCS, n=121†

(Continued)

0.005

<0.001

0.17

0.008

<0.001

0.45

0.52

0.52

0.94

0.88

0.27

0.45

<0.001

P value
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393 (154, 118, 121)

393 (154, 118, 121)

393 (154, 118, 121)

393 (154, 118, 121)

393 (154, 118, 121)

393 (154, 118, 121)

Hyperlipidemia

Arrhythmia

Diabetes

Chronic kidney disease

Myocardial infarction

Pulmonary hypertension

79 (20)

136 (35)

145 (37)

181 (46)

229 (58)

234 (60)

239 (61)

4.4±2.1

116 (30)

303 (86)

35 (23)

56 (36)

71 (46)

85 (55)

99 (64)

95 (62)

102 (66)

5.0±2.2

25 (16)

129 (86)

4 (3)

6 (4)

86 (60)

45 (31)

6 (4)

0 (0)

0 (0)

NA

NA

NA

NA

NA

NA

Long-term MCS
candidates, n=154†

28 (24)

40 (34)

39 (33)

53 (45)

69 (58)

68 (58)

67 (57)

4.2±2.1

37 (32)

64 (79)

4 (3)

5 (12)

22 (52)

12 (29)

1 (2)

1 (2)

1 (2)

352 (171, 692)

507 (255, 825)

10 (8)

5 (4)

87 (74)

16 (14)

HT candidates with MCS,
n=118†

16 (13)

40 (33)

35 (29)

43 (36)

61 (50)

71 (59)

70 (58)

3.9±1.8

54 (45)

110 (91)

2 (2)

2 (4)

22 (42)

18 (34)

6 (11)

3 (6)

2 (4)

NA

94 (43, 330)

3 (2)

39 (32)

51 (42)

28 (23)

HT candidates without
MCS, n=121†

0.08

0.83

0.008

0.005

0.07

0.77

0.21

<0.001

<0.001

<0.001

0.69

0.009

<0.001

<0.001

P value

BMI indicates body mass index; HT, heart transplantation; ICD, implantable cardioverter defibrillator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVEF, left ventricular ejection
fraction; MCS, mechanical circulatory support; NA, not applicable; NYHA, New York Heart Association; UNOS, United Network for Organ Sharing; VAD, ventricular assist device.
*Data are expressed as total number (total number of HT candidates with MCS, total number of HT candidates without MCS, total number of candidates ineligible for HT and scheduled for long-term MCS).
†
Data are expressed as mean±SD, number (percentage), or median (quartile 1, quartile 3).

393 (154, 118, 121)

393 (154, 118, 121)

Number of comorbidities

Hypertension

390 (153, 116, 121)

History of smoking

13 (5)

Not recorded/documented

352 (150, 81, 121)

130 (55)

<20, severe

ICD device in place at
enrollment

75 (32)

20 to 29, moderate/severe

10 (3)

13 (5)

30 to 39, moderate

393 (154, 118, 121)

4 (2)

Temporary MCS at
enrollment

3 (1)

.40 to 49, mild

238 (143, 42, 53)

LVEF closest to date of
surgery

352 (171, 692)

>50, normal

118 (NA, 118, NA)

Length of time on VAD from
implant to enrollment, d

252 (61, 629)

13 (5)

7

160 (NA, 67, 93)

44 (18)

2

Length of time on UNOS
waiting list at enrollment, d

138 (58)

1B

Total sample, n=393†

44 (18)

239 (NA, 118, 121)

Available sample total,
by group*

1A

UNOS status at enrollment

Variable
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Total sample, n=393†
55±23

382 (144, 118, 120)
382 (144, 118, 120)

EQ-5D-3L VAS score

EQ-5D-3L VAS score, by 25-point ranges

135 (36)
49±28
58±26
35±27
46±30
47±23

381 (143, 118, 120)
380 (143, 118, 119)
380 (143, 118, 119)
370 (137, 117, 116)
383 (145, 118, 120)
383 (145, 118, 120)
364 (132, 115, 117)
383 (145, 118, 120)
383 (145, 118, 120)

EQ-5D-3L usual activities, percent with
problems

EQ-5D-3L pain/discomfort, percent with
problems

EQ-5D-3L anxiety/depression, percent with
problems

KCCQ-12 physical limitation

KCCQ-12 symptom frequency

KCCQ-12 quality of life

KCCQ-12 social limitation

KCCQ-12 overall summary score

KCCQ-12 overall summary score, by 25-point
ranges

210 (55)

382 (147, 115, 120)
359 (141, 108, 110)
209 (51, 89, 69)
183 (37, 78, 68)

STAI-state total score

MoCA total score

Six-min walk, m

Gait speed, m/s

1.1±0.3

309±121

25.0±3.3

37±11

6.4±5.2

92 (64)

0.9±0.3

204±115

23.8±3.6

39±11

8.2±5.9

49 (33)

4 (3)

34 (23)

49 (34)

58 (40)

35±21

34±28

23±23

46±24

38±27

62 (43)

74 (52)

113 (79)

67 (47)

1.1±0.3

348±106

25.4±2.9

35±12

4.7±4.5

16 (14)

28 (24)

53 (45)

30 (25)

7 (6)

60±21

60±26

51±27

71±22

59±26

41 (35)

54 (46)

71 (60)

32 (27)

54 (46)

50 (42)

57 (48)

9 (8)

2 (2)

68±18

HT candidates with
MCS, n=118†

1.1±0.3

336±96

26.3±2.7

34±10

5.9±4.1

23 (19)

19 (16)

36 (30)

49 (41)

16 (13)

49±22

47±30

35±25

61±26

53±26

32 (27)

66 (55)

78 (65)

25 (21)

64 (54)

29 (24)

42 (35)

38 (32)

11 (9)

54±23

HT candidates without
MCS, n=121†

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.021

0.32

0.003

<0.001

0.010

<0.001

<0.001

P value

EQ-5D-3L VAS score indicates EuroQol-5 Dimension Questionnaire Visual Analog Scale (score range 0=worst to 100=best imaginable health state); HT, heart transplantation; KCCQ-12, Kansas City Cardiomyopathy
Questionnaire–12 (score range: 0=worst to 100=best health status); MCS, mechanical circulatory support; MoCA, Montreal Cognitive Assessment (score range: 0=worst to 30=best score; cognitive dysfunction is
defined as a MoCA score<26); PHQ-8, Personal Health Questionnaire–8 (depression screen; score range 0=less to 24=worse depression); and STAI-state, State-Trait Anxiety Inventory–state form (score range 20=less
to 80=worse anxiety).
*Data are expressed as total number (total number of HT candidates with MCS, total number of HT candidates without MCS, total number of candidates ineligible for HT and scheduled for long-term MCS).
†
Data are expressed as mean±SD or number (percentage).

382 (147, 115, 120)

PHQ-8 total score

88 (23)

51 (13)
382 (147, 115, 120)

75 to 100

PHQ-8≥10

128 (33)
123 (32)

25 to 49

50 to 74

81 (21)

0 to 24

194 (51)

262 (69)

124 (33)

380 (143, 118, 119)
380 (143, 118, 119)

EQ-5D-3L mobility, percent with problems

EQ-5D-3L self-care, percent with problems

51 (35)

150 (39)
98 (26)

50 to 74

75 to 100

19 (13)

52 (36)

35 (9)
99 (26)

0 to 24

22 (15)

46±23

Long-term MCS
candidates, n=154†

25 to 49

Variable

Available sample
total (by group)*

Table 2. Patient Questionnaires, Interview, and Performance-Based Assessments Completed at Baseline
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of life than the 2 HT candidate groups, whereas HT
candidates with MCS had the highest domain scores
among the 3 groups (Table 2).

Factors Associated With HRQOL in
Patients Awaiting HT and Long-Term MCS
We identified minimal variability among centers and
therefore chose not to control for center effects.
Multicollinearity among independent variables was
minimal. Significant variables from the univariable
models (Table S5) were included in the multivariable
models. In the multivariable model for the EQ-5D-3L
VAS score, being an HT candidate with MCS was associated with an 8.6-point increase (95% CI, 2.7–14.4;
P=0.004) in the VAS score compared with HT candidates without MCS. Decreased 6MWT distance and
more depressive symptoms were associated with a
decreased EQ-5D-3L VAS score and along with patient group explained 33% of the variance (Table 3).
Patient group was not significantly associated with the
KCCQ-12 OSS in the multivariable model. Increased
depressive symptoms, decreased 6MWT distance,
and higher NHYA class were associated with decreased HRQOL using the KCCQ-12 OSS, explaining
58% of variance (Table 3).
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DISCUSSION
Guided by our theoretical framework, we have extended knowledge of HRQOL in adult patients to
those who are 60 to 80 years of age before advanced
surgical therapies. In addition, we have expanded on
baseline findings from studies regarding intended
goal of therapy (ie, INTERMACS, MOMENTUM 3
trial, and the European study by Emin et al)8,12,15 by
comparing HRQOL among older patients who were
awaiting HT with or without MCS or long-term MCS
if ineligible for HT. Key baseline findings in this older
cohort of patients with HF from the SUSTAIN-IT study
were that overall HRQOL was poor to fair, and along
with domains of HRQOL, important differences were
detected among groups (ie, worse before long-term
MCS), thus supporting our first hypothesis that baseline overall and domain-specific HRQOL of long-term
MCS candidates would be different from baseline
HRQOL of the 2 HT candidate groups. Furthermore,
we identified factors (ie, patient group, indicators
of HF severity, and psychological factors) associated with worse baseline HRQOL for older patients
with advanced HF, which supported our second
hypothesis.
Notably, long-term MCS candidates who had worse
HRQOL, compared with both HT candidate groups,
were older and had more comorbidities (including diabetes and chronic kidney disease) and also had a higher

Quality of Life and Advanced Heart Failure

NYHA class, lower left ventricular ejection fraction, and
lower 6MWT and gait speed, which suggest a higher
severity of HF. Thus, it is perhaps not unexpected that
compared with older HT candidates, older long-term
MCS candidates had significantly worse overall generic
and HF-specific HRQOL, which are clinically important
differences.17,20,21 Our findings are partially supported
by findings from the observational ROADMAP (Risk
Assessment and Comparative Effectiveness of Left
Ventricular Assist Device and Medical Management)
study (overall mean±SD age, 63±13 years), which
enrolled 2 groups of patients with advanced HF who
were ambulatory: those scheduled for long-term MCS
and those who remained on optimal medical management. ROADMAP investigators reported that HRQOL
was lower at baseline in patients with long-term MCS
compared with those on optimal medical management
(45±20 versus 58±20, respectively).11 In contradistinction, INTERMACS investigators and MOMENTUM 3
trial investigators detected no clinically important differences in baseline overall HRQOL between adult
HT candidates with MCS (which included patients
with BTC MCS in the MOMENTUM 3 trial) and those
awaiting long-
term MCS.12,15 Differences in findings
between these 2 studies and our study are unclear
but may be attributed to age differences in groups
among studies. For example, the mean±SD ages of
candidates for DT MCS and candidates for BTT/BTC
MCS in the MOMENTUM 3 trial were 63±12 years of
age and 55±12 years of age, respectively, whereas the
mean±SD ages for long-term MCS (ie, DT) candidates
and HT candidates with MCS (BTT) in the SUSTAIN-IT
study were 69±5 years of age and 64±3 years of age,
respectively. Also, MOMENTUM 3 trial investigators
combined patients with BTT and BTC MCS (including
those who were likely, moderately likely, and unlikely to
become transplant eligible) into 1 group,12 which may
have influenced their findings, as moderately likely and
unlikely patients with BTC MCS may have been more
similar to DT candidates than HT candidates.
In addition, older patients awaiting HT with MCS
had the highest HRQOL scores, which most likely represents the positive impact of MCS on reducing HF
symptoms and improving functional capacity. Emin
et al8 also reported clinically important differences in
overall HRQOL in their younger cohort of patients, favoring HT candidates with MCS compared with those
on medical therapy (KCCQ-12 OSS, 52.6±22.0 versus
33.3±21.1, respectively).
Few studies have identified factors associated with
HRQOL in older patients with HF awaiting advanced
surgical therapies. The association between being
an HT candidate with MCS and better HRQOL may
be attributed to improved health on MCS and the anticipation of HT. We previously reported that patients
awaiting HT with MCS commented that the device
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Table 3. Factors Associated With Health-Related Quality of Life in Patients Awaiting HT and Long-Term MCS Using
Multivariable Linear Regression Models
Effect

Effect size

95% Confidence limits

P value

63.7

27.8

99.7

<0.001

Long-term MCS candidates

−1.3

−8.0

5.4

0.71

HT candidates with MCS

8.6

2.7

14.4

0.004

HT candidates without MCS

Reference

Reference

Reference

Reference

Patient White race

−2.2

−8.1

3.7

0.50

Patient PHQ-8 total score

−1.4

−1.9

−0.8

<0.001

0

−9.8

−17.7

−2.0

0.015

1 to 183

−6.9

−15.0

1.1

0.09

184 to 300

−2.2

−9.9

5.6

0.58

301 to 378

0.9

−6.3

8.1

0.81

>378

Reference

Reference

Reference

Reference

Patient history of arrhythmia

−3.4

−7.6

0.8

0.11

Patient history of chronic
kidney disease

−3.3

−7.7

1.2

0.15

Patient history of diabetes

−2.6

−6.8

1.7

0.23

Patient history of hypertension

−1.6

−5.9

2.8

0.48

1

Reference

Reference

Reference

Reference

2

−2.6

−13.4

8.2

0.63

3

−8.0

−18.7

2.7

0.14

4

−6.2

−17.8

5.3

0.29

Patient history of smoking

2.9

−1.8

7.6

0.23

Patient STAI-state total score

−0.03

−0.3

0.2

0.82

Patient male sex

−3.3

−8.8

2.2

0.24

Patient age

0.3

−0.2

0.8

0.30

65.4

36.4

94.3

<0.001

Long-term MCS candidates

−0.5

−5.8

4.7

0.84

HT candidates with MCS

3.7

−0.9

8.3

0.11

HT candidates without MCS

Reference

Reference

Reference

Reference

−2.2

−2.6

−1.8

<0.001

0

−15.9

−22.1

−9.7

<0.001

1 to 183

−16.3

−22.6

−10.0

<0.001

184 to 300

−7.3

−13.4

−1.2

0.019

301 to 378

−3.8

−9.5

1.9

0.19

>378

Reference

Reference

Reference

Reference

Medicare/Medicaid

−1.8

−5.4

1.8

0.32

Private insurance

Reference

Reference

Reference

Reference

Patient history of diabetes

−1.4

−4.7

1.9

0.41

Reference

Reference

Reference

Reference

2

EQ-5D VAS score (R =0.33)
Intercept
Patient group

Patient 6-min walk, m

Patient NYHA class at enrollment
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2

KCCQ-12 overall summary score (R =0.58)
Intercept
Patient group

Patient PHQ-8 total score
Patient 6-min walk, m

Patient insurance type

Patient NYHA class at enrollment
1

(Continued)
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Table 3. Continued
Effect

Effect size

95% Confidence limits

P value

2

−2.7

−11.2

5.8

0.53

3

−8.9

−17.2

−0.5

0.039

4

−12.1

−21.2

−3.1

0.009

Patient history of smoking

1.4

−2.2

5.1

0.45

Patient STAI-state total score

−0.03

−0.2

0.2

0.75

Patient age

0.3

−0.2

0.7

0.26

EQ-5D VAS indicates EuroQol Visual Analog Scale; HT, heart transplantation; KCCQ-12, Kansas City Cardiomyopathy Questionnaire–12; MCS, mechanical
circulatory support; NYHA, New York Heart Association; PHQ-8, Personal Health Questionnaire–8; and STAI, State-Trait Anxiety Inventory.
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reduced HF symptoms and improved participation in
usual activities, yet patients were also anxious to undergo HT and “get on with life.”28 Less distance walked
on the 6MWT and its association with worse HRQOL
is also logical, as it reflects impaired functional capacity, which was also found by Stehlik and colleagues5 in
their report from the REVIVAL study. Similar to our findings, Stehlik et al5 also reported that a higher NYHA
class was associated with worse HRQOL at baseline.
Notably, significantly more long-term MCS candidates
in our study were NYHA class IV than both HT candidate groups. Given the strength of the association
of a higher NYHA class with a decrease in HRQOL,
monitoring NYHA class in long-term MCS candidates
is especially warranted. The association between depressive symptoms and HRQOL in patients with HF is
well supported in the literature in, on average, middle-
aged and older-
aged cohorts.11,29,30 Rutledge and
31
colleagues reported that depression was more prevalent in patients with HF with higher NYHA class, also
providing support for our findings.
This baseline report from the SUSTAIN-IT study provides valuable information for shared decision-making
discussions with older patients with advanced HF when
considering surgical treatment options and regarding
targets for HRQOL-related treatment. It is well known
that HRQOL influences preferences for treatment.32 A
critical question is the following: Will older patients with
advanced HF incur more HRQOL-related benefit from
HT or long-term MCS? The answer to this question
is complex, as symptom burden, functional capacity, comorbidities, other outcomes (eg, survival), and
postoperative risks and benefits must be considered.
Our “head-to-head” comparison of baseline HRQOL
among older patients before these surgical therapies
partially addresses this question. Understanding differences in baseline HRQOL in our 3 groups of older
patients provides critical information that may be useful
to gauge the amount of improvement in HRQOL after
HT or long-term MCS that may ultimately contribute
to identifying which therapy conveys more HRQOL-
related benefit. In support of this notion, findings from
our INTERMACS study of HRQOL by severity of HF

from before through 1 year after MCS implant (patient
mean±SD age, 53±12 years of age) revealed greater
gains in HRQOL by patients with lower INTERMACS
profiles (ie, more-severe HF) than patients with higher
INTERMACS profiles (ie, less-
severe HF) despite
postimplant adverse events.10 Thus, sharing baseline
HRQOL with older patients regarding potential surgical
treatment options, that in the opinion of the clinician
may provide benefit, contributes to a more informed
shared decision-making process, which has been well
described in the literature,33 and importantly is iterative,
as patient preferences for survival versus HRQOL can
change over time, often based on symptom burden
and functional capacity.34
Our study also contributes to a better understanding of differences in HRQOL in older patients before
HT and long-
term MCS, especially domain-
specific
HRQOL (eg, problems with mobility, usual activities,
social functioning, anxiety/depression, and pain/discomfort and potentially worsening HF symptoms),
which provides important individualized targets for
treatment. We and others recommend assessment
of baseline HRQOL by self-report, rather than proxy
(eg, physicians and family members), which can be
discrepant, either overestimating or underestimating
HRQOL.18,35 These data can be captured and scored
electronically in real time. Careful and frequent monitoring of older patients’ HF trajectory, NYHA class,
symptoms, HRQOL (both overall and domains), functional capacity,33,36 and subsequent development of a
treatment plan, including consultation with the palliative
care team and allied health team members, especially
physical therapists, psychologists, and social workers,
may contribute to enhanced HRQOL and improved
health while awaiting HT or long-term MCS. Notably,
older long-term MCS candidates in our study reported
more problems with physical function (ie, mobility, self-
care, and usual activities) and mood (ie, anxiety and
depression) than both groups of older HT candidates.
Assessment of these HRQOL domains in this group
of patients with advanced HF and the development
of a treatment plan is especially warranted. Our recommendations are partially supported by Dew et al,37
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who identified key domains for evaluation of candidacy
for cardiothoracic transplantation and MCS, including
evaluations of patients’ current mental and social histories and understanding of their current illness, impact on daily functioning, symptoms, and treatment.
Ultimately, understanding and subsequently treating
HRQOL-
focused problems while older patients with
advanced HF await HT or long-term MCS may contribute to better outcomes after these surgical therapies.
Subsequent analyses from the SUSTAIN-IT study
will compare changes over time in overall and domain-
specific HRQOL early (baseline to 6 months) and later
(baseline to 2 years) after HT (with or without MCS as
a pretransplant management strategy) versus long-
term MCS and identify factors related to change in
HRQOL. Future findings from our study may increase
knowledge of this patient-centric outcome so that clinicians may better inform older patients with advanced
HF considering these treatment options as to which
option may convey more HRQOL-related benefit and
initiate postoperative HRQOL-focused treatment, especially regarding domain-specific findings.
A limitation of our study is that older patients enrolled in the SUSTAIN-IT study were prescreened and
deemed eligible/awaiting advanced surgical therapies; thus, their HRQOL may not be reflective of the
broader population with advanced HF. Also, a substantial number of patients in our total patient pool
were not approached as a result of being too sick or
were approached and refused participation for similar reasons, which may have resulted in an overestimation of HRQOL. In addition, our sample was fairly
homogeneous, and more patients had more than
a high school education than samples from other
studies, which may limit generalizability. Lastly, lower
completion rates of performance-based measures,
which varied by site, may also have influenced our
findings, although we used a robust method to impute data for the 6MWT.

CONCLUSIONS
These findings demonstrate important differences
in overall and domain-specific HRQOL of older patients with advanced HF before HT or long-term MCS.
Understanding differences in HRQOL may guide decisions toward more personalized, advanced HF therapies. Older patients before long-term MCS are an
especially appropriate target for these therapies given
their worse HRQOL compared with both HT candidate
groups.
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Table S1. Assessments Completed by Patients at Baseline.
Measure

Description of Measure
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Self-report Measures
EQ-5D-3L19
Generic Overall Health-related Quality of Life (HRQOL) and dimensions:

Single item rating current health status uses a vertical graduated (0-100)
20cm visual analog scale (VAS). Mean VAS scores are calculated.

5 dimensions: mobility, self-care, usual activities, pain/discomfort, and
anxiety/ depression with 3 levels of response (no problems,
some/moderate problems, and extreme problems).
Kansas City
Heart failure-specific Overall HRQOL and domains:
Cardiomyopathy
 12-item disease specific questionnaire that measures HRQOL in patients
Questionnaire
with heart failure.
(KCCQ-12)20
 Four domains: physical limitations, symptom frequency, social limitations,
and quality of life, and an overall summary score, combining the domains.
Responses are set up as Likert scales. Scale scores are transformed to 0100; higher scores = better health-related quality of life.
Personal Health Mental HRQOL domain:
Questionnaire
 8-item screen for depression, based on the first eight criteria on which the
(PHQ-8)22
diagnosis of DSM-IV depressive disorder is based.
 Subjects indicate how often they have been bothered by depressive
symptoms over the previous two weeks on a scale of 0=not at all to
3=nearly every day.
 A summary score is calculated, with possible scores ranging from 0 to 24.
Higher scores indicate higher levels of depressive symptoms. Scores >10
indicate the need for clinical assessment and management.
State-Trait
Mental HRQOL domain:
Anxiety
 20 self-report items assessing current levels of anxiety.
Inventory -State
 Subjects use a four-point Likert scale ranging from (1) not at all to (4) very
form (STAImuch so. Higher scores = greater state anxiety.
State)23
Performance-based Measures
Six minute walk Physical domain:
test (6MWT)25
 Measure of physical functional capacity, consists of having a patient walk
for 6 minutes in an enclosed hallway, free of traffic and distractions, with
distance measured in meters.



5-meter gait
speed26

Patients are instructed to walk steadily to cover as much distance as
possible during the 6 minutes. At the end of the walk, the total time (if less
than 6 minutes) and distance covered is recorded. If a patient is bedbound, a score of “0” may be assigned.36

Frailty:


Clinical marker of frailty, used in an elderly cardiac surgical population.26
Conducted in a well-lit, unobstructed hallway with markings at 0 and 5
meters.

Patients are instructed to walk at a comfortable pace; canes and walkers
are allowed. If a patient cannot walk, data are considered missing. This
test is performed three times and averaged. Slower gait speed = longer
walk time over 5 meters (m/sec).
Interview Administered Measure
Montreal
Cognitive dysfunction:

Cognitive
10-minute screening instrument (worst-to-best total score range=0-30),
Assessment
includes 7 cognitive domains.

(MoCA)24
Cognitive dysfunction: (MoCA total score less than 26).


.
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Table S2. Completion of Assessments at Baseline.
HT* Candidates
Patient Baseline
Forms

(with and without MCS)
Completed/Expected (%)

Long-term MCS†
Candidates
Completed/Expected (%)

Total
Completed/Expected (%)

Self-report Assessments
EQ-5D-3L‡

237/239 (99%)

142/154 (92%)

379/393 (96%)

KCCQ-12§

237/239 (99%)

143/154 (93%)

380/393 (97%)

PHQ-8ǁ

235/239 (98%)

147/154 (95%)

382/393 (97%)

STAI-state#

235/239 (98%)

147/154 (95%)

382/393 (97%)

Interviewer-administered Assessment
MoCA**

218/239 (91%)

141/154 (92%)

359/393 (91%)
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Performance-based Assessments
Five Meter Gait Speed

146/239 (61%)

37/154 (24%)

183/393 (47%)

Six Minute Walk Test

158/239 (66%)

51/154 (33%)

209/393 (53%)

*HT = heart transplantation
† MCS

= mechanical circulatory support
EQ-5D-3L = EuroQol-5 dimension-3L
§ KCCQ-12 = Kansas City Cardiomyopathy Questionnaire-12
ǁ PHQ-8 = Personal Health Questionnaire
# STAI-state = State-Trait Anxiety Inventory-state form
**MoCA = Montreal Cognitive Assessment.
‡

Table S3. Patient Baseline Reasons for Missing Data for Performance-based Measures.
Available
Variable
Six Minute Walk Missing Status, No. (%)
.

Form Incomplete/Reason Not Provided

.

Test Not Done (Reason Provided)

Reason Six Minute Walk Not Done, No. (%)

sample
total (by group)

Total sample
(n=393)

Long-term
MCS*
candidates
(n=154)

HT†
candidates
with MCS
(n=118)

HT
candidates
without MCS
(n=121)

184(103,29,52)

0.67
1 (1%)

1 (1%)

0 (0%)

0 (0%)

183 (99%)

102 (99%)

29 (100%)

52 (100%)

183(102,29,52)

0.030
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.

Patient Refused, Unable to Walk

30 (16%)

22 (22%)

3 (10%)

5 (10%)

.

Patient Refused, Too Tired/Sick

89 (49%)

50 (49%)

13 (45%)

26 (50%)

.

Patient Refused, No Time/Too Busy

6 (3%)

1 (1%)

1 (3%)

4 (8%)

.

Patient Refused, No Reason Given

1 (1%)

1 (1%)

0 (0%)

0 (0%)

.

Did Not Approach Due to Patient Health Status

26 (14%)

17 (17%)

2 (7%)

7 (13%)

.

Coordinator Forgot/No Time

2 (1%)

1 (1%)

0 (0%)

1 (2%)

.

‡

Collected For INTERMACS Within Visit Window

5 (3%)

4 (4%)

1 (3%)

0 (0%)

.

Other

24 (13%)

6 (6%)

9 (31%)

9 (17%)

Five Meter Gait Speed Missing Status, No. (%)
.

Form Incomplete/Reason Not Provided

.

Test Not Done (Reason Provided)

Reason Five Meter Gait Speed Not Done, No. (%)

p-value

210(117,40,53)

0.67
1 (0%)

1 (1%)

0 (0%)

0 (0%)

209 (100%)

116 (99%)

40 (100%)

53 (100%)

209(116,40,53)

0.002

.

Patient Refused, Unable to Walk

32 (15%)

25 (22%)

3 (8%)

4 (8%)

.

Patient Refused, Too Tired/Sick

101 (48%)

59 (51%)

16 (40%)

26 (49%)

.

Patient Refused, No Time/Too Busy

8 (4%)

1 (1%)

3 (8%)

4 (8%)

.

Patient Refused, No Reason Given

2 (1%)

2 (2%)

0 (0%)

0 (0%)

.

Did Not Approach Due to Patient Health Status

31 (15%)

20 (17%)

4 (10%)

7 (13%)

.

Coordinator Forgot/No Time

5 (2%)

2 (2%)

2 (5%)

1 (2%)

.

Other

30 (14%)

7 (6%)

12 (30%)

11 (21%)

* MCS

= mechanical circulatory support
= heart transplantation
‡ INTERMACS = Interagency Registry for Mechanically Assisted Circulatory Support
† HT
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Table S4. Patient Baseline EQ-5D-3L Dimension Scores by 3 Levels of Problems.

Variable

Available
sample
total (by group)

EQ-5D-3L‡

Mobility, No. (%)

Total sample
(n=393)

Long-term MCS*
candidates
(n=154)

HT† candidates
with MCS (n=118)

HT candidates
without MCS
(n=121)

380(143,118,119)

<0.001

.

No Problems in Walking About

170 (45%)

51 (36%)

64 (54%)

55 (46%)

.

Some Problems in Walking About

179 (47%)

68 (48%)

54 (46%)

57 (48%)

.

Confined to Bed

31 (8%)

24 (17%)

0 (0%)

7 (6%)

EQ-5D-3L Self-Care, No. (%)

380(143,118,119)

<0.001

.

No Problems with Self-Care

256 (67%)

76 (53%)

86 (73%)

94 (79%)

.

Some Problems Washing or Dressing
Myself

101 (27%)

46 (32%)

32 (27%)

23 (19%)

.

Unable to Wash or Dress Myself

23 (6%)

21 (15%)

0 (0%)

2 (2%)

EQ-5D-3L Usual Activities, No. (%)

381(143,118,120)

<0.001
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.

No Problems with Performing My
Usual Activities

119 (31%)

30 (21%)

47 (40%)

42 (35%)

.

Some Problems with Performing My
Usual Activities

193 (51%)

65 (45%)

66 (56%)

62 (52%)

69 (18%)

48 (34%)

5 (4%)

16 (13%)

.

Unable to Perform My Usual

p-value

Activities
EQ-5D-3L Pain/Discomfort, No. (%)

380(143,118,119)

0.23

.

No Pain or Discomfort

186 (49%)

69 (48%)

64 (54%)

53 (45%)

.

Moderate Pain or Discomfort

183 (48%)

67 (47%)

52 (44%)

64 (54%)

.

Extreme Pain or Discomfort

11 (3%)

7 (5%)

2 (2%)

2 (2%)

EQ-5D-3L Anxiety/Depression, No. (%)

380(143,118,119)

0.08

.

Not Anxious or Depressed

245 (64%)

81 (57%)

77 (65%)

87 (73%)

.

Moderately Anxious or Depressed

126 (33%)

57 (40%)

38 (32%)

31 (26%)

.

Extremely Anxious or Depressed

9 (2%)

5 (3%)

3 (3%)

1 (1%)

* MCS = mechanical circulatory support
† HT = heart transplantation
‡ EQ-5D-3L = EuroQol -5D-3L Questionnaire
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Table S5. Factors Associated with Health-related Quality of Life in Patients Awaiting
Heart Transplantation and Long-term Mechanical Circulatory Support using
Univariable Linear Regression Models.

Effect

n
Effect
Available
Size
Outcome: EQ-5D* VAS Score
Sample (Reference = HT† candidates without MCS )


Long-term MCS‡ candidates



HT candidates with MCS

382

95% Confidence
Interval

pvalue

-8.5

-13.8

-3.3

0.001

13.7

8.2

19.1

<0.001
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Age, years
Male

382
382

-0.6
-4.0

-1.2
-9.8

-0.1
1.9

0.014
0.18

Race (White)

380

-4.9

-11.2

1.3

0.12

Education > High School

357

-2.9

-8.0

2.2

0.27

History of Smoking

379

4.1

-1.0

9.2

0.11

Arrhythmia

382

-5.3

-10.0

-0.5

0.030

Kidney Disease

382

-5.4

-10.2

-0.5

0.030

Diabetes

382

-5.5

-10.2

-0.8

0.021

Hypertension

382

-3.7

-8.5

1.1

0.12

-8.3

-19.9

3.2

0.16

-21.4
-28.7

-32.2
-39.3

-10.6
-18.2

<0.001
<0.001

NYHA Class at Enrollment (Reference = 1)


2

 3
 4
Patient Six Minute Walk (meters)
(Reference is >378)

371



0



1 - 183




-23.1

-30.0

-16.4

<0.001

-18.6

-26.0

-11.3

<0.001

184 - 300

-9.6

-17.4

-1.8

0.016

301 - 378

-2.5

-10.0

4.9

0.50

378
-2.0
-2.4
378
-0.6
-0.8
351
0.9
0.1
Outcome: KCCQ-12** Overall Summary Score
Sample (Reference = HT candidates without MCS)

-1.5
-0.4
1.6

<0.001
<0.001
0.022

381

PHQ-8§ Total Score
STAIǁ Total Score
MoCA# Total Score




Long-term MCS candidates
HT candidates with MCS

383

-13.6

-18.7

-8.5

<0.001

11.0

5.6

16.4

<0.001
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Age, years

383

-1.0

-1.5

-0.4

<0.001

Education > High School

358

-3.4

-8.5

1.8

0.20

Insurance Type: Private Insurance vs
Medicare/Medicaid

383

5.6

0.8

10.4

0.021

Currently Working

359

8.4

1.9

14.8

0.011

History of Smoking

380

5.1

-0.01

10.2

0.050

Diabetes

383

-5.7

-10.3

-1.0

0.018

-11.1

-21.9

-0.3

0.043

-25.2
-38.3

-35.2
-48.2

-15.1
-28.5

<0.001
<0.001

2.8
17.6

-2.8
11.6

8.3
23.6

0.32
<0.001

NYHA Class at Enrollment (Reference = 1)


2

 3
 4
Patient Six Minute Walk (meters)
(Reference is >378)
 0
 1 - 183

372

382

 184 - 300
 301 - 378
PHQ-8 Total Score
STAI Total Score
MoCA Total Score
* EQ-5D VAS = EuroQol visual analog scale
† HT = heart transplantation
‡ MCS = mechanical circulatory support
§ PHQ-8 = Personal Health Questionnaire-8
ǁ STAI-state = State-Trait Anxiety Inventory-state form
# MoCA = Montreal Cognitive Assessment
** KCCQ-12 = Kansas City Cardiomyopthy Questionnaire

379
379
352

26.1
35.2
-2.9
-0.8
1.77

20.5
29.2
-3.3
-1.0
1.0

31.8
41.2
-2.6
-0.7
2.4

<0.001
<0.001
<0.001
<0.001
<0.001
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Figure S1. Histogram for the three groups of candidates as individual overlays, with a density curve that represents the entire
cohort.
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HT-MCS = heart transplant candidate with mechanical circulatory support prior to transplantation, Long-term MCS = advanced heart
failure patient prior to long-term mechanical circulatory support, and HT-NonMCS = heart transplant candidate without mechanical
circulatory support prior to transplantation.

